Tandem-core hepatitis B core antigen (HBcAg) virus-like particles (VLPs), in which two
HBcAg monomers are joined together by a peptide linker, can be used to display two …

The traditional “one-size-fits-all” mass production model commonly used in biologics
manufacturing is insufficient to accommodate the advent of personalised medicines and the …

Since the first effort to recombinantly express the hepatitis B core protein (HBc) in bacteria,
the remarkable virion-like structure has fuelled interest in unraveling the structural and …

Background The lack of a universal influenza vaccine is a global health problem. Interest is
now focused on structurally conserved protein domains capable of eliciting protection …

The core protein of the hepatitis B virus, HBcAg, assembles into highly immunogenic virus-
like particles (HBc VLPs) when expressed in a variety of heterologous systems. Specifically …

Virus-like particles (VLPs) are supramolecular protein assemblies with the potential for
unique and exciting applications in synthetic biology and medicine. Despite the attention …

Virus-like particles (VLPs) are promising molecular structures for the design and
construction of novel vaccines, diagnostic tools, and gene therapy vectors. Size, oligomer …

Virus-like particle (VLP) technology is a promising approach for the construction of novel
vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived …

Influenza virus is a highly infectious respiratory pathogen that results in severe morbidity and
mortality. The current licensed trivalent vaccine formulations in the US are made from virus …

Virus-like particles (VLPs) have been extensively explored as nanoparticle vehicles for
many applications in biotechnology (eg, vaccines, drug delivery, imaging agents …